MOTS-c vs ANP (Atrial Natriuretic Peptide)
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
MOTS-c
MOTS-c (Mitochondrial Open Reading Frame of the Twelve S rRNA type-c) is a mitochondrial-derived peptide that plays a key role in metabolic regulation and has emerged as a significant longevity research target.
Full details →ANP (Atrial Natriuretic Peptide)
ANP is a cardiac hormone released by atrial myocytes in response to stretch. It promotes natriuresis, diuresis, and vasodilation, playing key roles in blood pressure and fluid regulation.
Full details →Side-by-Side Comparison
| Aspect | MOTS-c | ANP (Atrial Natriuretic Peptide) |
|---|---|---|
| Mechanism | Activates AMPK pathway, enhances glucose uptake in skeletal muscle, improves insulin sensitivity, and regulates mitochondrial function. Acts as a metabolic hormone affecting whole-body energy homeostasis. | Binds to natriuretic peptide receptors (NPR-A) to activate guanylyl cyclase, producing cGMP. This leads to vasodilation, increased kidney filtration, and inhibition of the renin-angiotensin-aldosterone system. |
| Typical Dosage | Research protocols typically use 5-10mg administered subcutaneously several times per week. Optimal dosing not yet established. | Clinical use: Carperitide (recombinant ANP) used in Japan for acute heart failure at 0.1mcg/kg/min IV infusion. |
| Administration | Subcutaneous injection. Often combined with exercise protocols as it enhances exercise capacity and metabolic adaptation. | Intravenous infusion only for clinical applications. Short half-life (~2 minutes) requires continuous administration. |
| Side Effects | Limited human data. Animal studies show good tolerability. May affect energy levels and exercise performance. | Hypotension (dose-limiting), headache, nausea, and potential arrhythmias at high doses. |
| Best For |